Achieving A Resilient Flu Vaccine Supply Chain Requires Retooling Most Of The Links
Executive Summary
Expert panel draws lessons from COVID-19 in pressing for new manufacturing technologies, greater global coordination, more resilient supply chains and trained vaccine plant workers ready to “parachute” into the next outbreak.
You may also be interested in...
BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days
Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.
Pandemic Response Strains Global Biopharmaceutical Reactor Capacity
Distress grows as manufacturers wait for suppliers to boost production. One idea: stretch inventories by qualifying single-use bioreactors for reuse.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.